2 Works
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Adis Journals on behalf of:, Amy S. Paller, Elaine C Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Mercedes E. Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A. Levit & Randy Prescilla
The above Video Abstract, Key Points and Plain Language Summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Adis Journals on behalf of:, Amy S. Paller, Elaine C Siegfried, Michael J. Cork, Andreas Wollenberg, Peter D. Arkwright, Mercedes E. Gonzalez, Benjamin Lockshin, Zhen Chen, Ashish Bansal, Noah A. Levit & Randy Prescilla
The above Key Points and Plain Language Summary represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite). © The authors, CC-BY-NC 2022